Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Combination therapy offers hope for AML patients facing drug resistance

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies. In a study published today in Cell Reports

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

In a study published today in Cell Reports Medicine, researchers analyzed more than 300 acute myeloid leukemia, or AML, patient samples and found that pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor currently approved for breast cancer, produced significantly stronger and more durable anti-leukemia activity than venetoclax alone. The findings were confirmed in human tissue samples, as well as in mouse models carrying human leukemia cells.

"Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective. That really motivated us to dig deeper into why it works so well - and why it appears to overcome resistance seen with current therapy," said Melissa Stewart, Ph.D., research assistant professor at OHSU and lead author of the study.

More than 20,000 Americans are diagnosed with AML each year, making it one of the most common types of leukemia - and one of the most aggressive.

A major challenge: Drug resistance

Since the drug was approved by the Food and Drug Administration in 2019, venetoclax combined with azacitidine has rapidly become a go-to treatment for many people with AML. But resistance remains a nearly universal problem.

"Unfortunately, almost everyone will eventually have drug resistance," said the study's corresponding author, Jeffrey Tyner, Ph.D., professor of cell, developmental and cancer biology in the OHSU School of Medicine.

This regimen has improved initial response rates and quality of life, but the five-year survival rate for AML is still only about 25 % to 40 %. We have a lot of work to do." Jeffrey Tyner, School of Medicine, OHSU

Tyner, a co-leader of the national Beat AML 1.0 program said the new study builds directly on the work of that national initiative to help transform and expand treatments for AML.

"This combination was nominated from the Beat AML data, and Dr. Stewart validated that prediction, showing not only that it works, but why," Tyner said.

The study found that AML cells exposed to venetoclax alone try to adapt by increasing protein production, a shift that helps them survive. Adding palbociclib, a drug approved for breast cancer, blocked this adaptation by regulating protein-production machinery inside the cell.

"Patient samples that responded strongly to the combination showed clear downregulation of genes involved in protein synthesis," Stewart said. "This was a big clue."

A genome-wide CRISPR screen also revealed that while venetoclax alone becomes more effective when protein-production genes are lost, the combination therapy does not rely on that same vulnerability - a sign the two drugs work together to shut down multiple survival pathways.

The research team tested the combination using mouse models implanted with human AML cells carrying mutations known to cause venetoclax resistance.

"In this model, venetoclax alone didn't extend survival at all - just as we'd expect based on the genetics," Stewart said. "But with the combination, the majority of mice lived 11 to 12 months. In fact, one mouse was still alive when the study ended."

A personal connection, following the data

Stewart says the project holds personal significance.

"I'm a breast cancer survivor and was treated here at OHSU, so I know what it's like to be a cancer patient," she said. "The hope that research and clinical trials can bring - that's what motivates me. Working on AML gave me a way to contribute."

Both researchers emphasized the importance of following scientific data even when it leads outside traditional boundaries.

"Some might ask why a breast cancer drug would work in AML," Tyner said. "But biology can be shared across very different cancers. This is a great example of why keeping an open mind matters and following the data where it leads."

Stewart said that the team is already evaluating other drugs similar to palbociclib - many of them also approved for breast cancer - to expand future clinical trial options. The researchers hope to move the combination toward clinical testing.

"We haven't tested it in patients yet, but based on everything we've seen, our prediction is that this combination would mitigate most known resistance mechanisms to the current standard therapy," Tyner said. "Making it a clinical reality will take work, but this is exactly why we do what we do."

Stewart, M. L., et al. (2025). CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. Cell Reports Medicine. DOI:10.1016/j.xcrm.2025.102526. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00599-3?_returnURL.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01In safety assessment, the consequences of being wrong are significant. How do you think about uncertainty and model limitations for safety and discovery?

Uncertainty and model limitations are critical in safety assessment. There is clearly greater potential for animal or human harm from an incorrect safety assessment than from making the wrong molecule in early discovery, although uncertainty matters in both contexts. It is important to distinguish different types of uncertainty. Aleatoric uncertainty reflects irreducible randomness in a task, while epistemic uncertainty is model-related, such as hallucinations or lack of knowledge. For LLM systems, we use multiple methods to measure consistency and we have built fact-checking approaches in which a separate LLM independently verifies the primary engine's outputs. For QSAR models, including our SAR work around seizure liability, we can use statistical metrics such as confidence intervals to quantify and communicate uncertainty. Understanding that uncertainty exists and communicating it in both safety and discovery is critical. Uncertainty metrics tell us where potential blind spots may exist in our modelling allowing us to take action to improve over time. This applies to both safety and discovery. The aim is not to pretend AI removes uncertainty, but to make uncertainty visible so scientists can make better-informed decisions. Download the Full PDF to Revisit James McDonagh's Insights on AI in Drug Safety Discovery

Source: www.news-medical.net ↗
02What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
03Why do so many of the compounds fail?

One of the main reasons why compounds fail is that they actually don't work in the patients they are tested in. We may have picked the wrong target since although we've actually created a molecule that, for example, inhibits the activity of the protein in the disease, it may actually turn out that over activity of that e protein isn't as important as we thought it was in that disease. The other reasons molecules fail now is primarily unexpected toxicity. You could take a molecule all the way through to phase 3 trials – the biggest trials in patients – and suddenly find that in your long-term, two-year carcinogenicity studies in animals, that you've got something that is quite cancer-provoking, so you have to stop development. Those are the two reasons: efficacy and toxicity. Somehow, we've got to find a way of trying to increase the chances of success or making the process less costly and leaner.

Source: www.news-medical.net ↗
04How will this discovery change cancer science?

This is a win for the field. Until now, we have been focused on immune therapies that might make tumors more vulnerable to the body's immune system, and on finding new chemotherapy combinations that kill cancer cells. This new treatment has given us a new focus, and I think it will spur a lot of scientific discovery over the next few years. There have only been a handful of KRAS researchers and their relevance to therapy was always questioned. That is about to change. The most important next step for the field is to better understand the biology of cancer. We know that many pancreatic tumors will eventually become resistant to daraxonrasib, and we need to understand how this happens. We also need to identify additional genetic pathways and treatments that can target them. That's how we will turn pancreas cancer from a deadly, deadly cancer into something we can manage-and one day, even cure.

Source: www.news-medical.net ↗
05What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →